 AUSTIN, Texas, July 22, 2021 PRNewswire -- VolitionRx Limited NYSE AMERICAN: VNRX Volition, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with researchers at two leading NHS Foundation Trusts on two studies in COVID-19 for which abstracts were released this week at the International Society on Thrombosis and Haemostasis ISTH Congress 2021. Dr. Jake Micallef, Chief Scientific Officer of Volition said We believe our Nu.Q NETs assay will have wide applicability for monitoring diseases with a NETs component such as COVID-19, sepsis, autoimmune diseases and cancer and potentially to risk stratify patients for treatment selection. 